CA
COLL icon

Cambridge Associates’s Collegium Pharmaceutical COLL Stock Holding History

Cambridge Associates’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-25,524
Closed -$504K – 45
2021
Q3 		$504K Buy
+25,524
New +$552K 0.04% 44

Other funds holding COLL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Cambridge Associates's COLL Position: Q4 2021 in Review

Cambridge Associates sold out of Collegium Pharmaceutical (COLL) in Q4 2021, closing a stake of 25,524 shares — an estimated $504K sold.

Cambridge Associates first reported a position in COLL in Q3 2021 and held it in 1 quarter. The position peaked at $504K in Q3 2021. 159 funds tracked by Wall St. Rank hold COLL as of Q4 2021.

  • Cambridge Associates reported no remaining Collegium Pharmaceutical position as of Q4 2021 after selling out during the quarter.
  • Cambridge Associates sold 25,524 Collegium Pharmaceutical shares in Q4 2021, an estimated $504K.
  • Cambridge Associates first reported a position in Collegium Pharmaceutical in Q3 2021 and held it in 1 quarter.
  • Cambridge Associates's Collegium Pharmaceutical position peaked at $504K in Q3 2021.
  • 159 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q4 2021.

Based on Cambridge Associates's 13F filing for Q4 2021, filed 11 Feb 2022.